Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | MAP2 | P11137 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770690 | 0.89 | MLKL (0.52) | MLKLGAAMTNR1BMTNR1ACHEK2 | |
| SCHEMBL12066577 | 0.86 | MLKL (0.59) | MLKLGAAFLT3CHEK2CYP1A2 | |
| SCHEMBL14770550 | 0.86 | FLT3 (0.40) | MLKLGAAFLT3CYP1A2MEN1 | |
| SCHEMBL14770701 | 0.86 | MLKL (0.49) | MLKLGAAMTNR1BMTNR1AFLT3 | |
| SCHEMBL14770470 | 0.85 | MLKL (0.48) | MLKLGAAMTNR1BMTNR1AFLT3 | |
| SCHEMBL14770608 | 0.85 | MLKL (0.48) | MLKLGAAMTNR1BMTNR1AFLT3 | |
| SCHEMBL12066599 | 0.84 | MLKL (0.45) | MLKLGAACYP1A2 | |
| SCHEMBL14770511 | 0.82 | MEN1 (0.44) | MLKLGAAMTNR1BMTNR1ACHEK2 | |
| SCHEMBL14770699 | 0.82 | MLKL (0.46) | MLKLGAAMTNR1BMTNR1ACHEK2 | |
| SCHEMBL14770471 | 0.82 | MEN1 (0.55) | MLKLGAAMTNR1BMTNR1ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | MLKL 2378/4885GAA 3586/4885MTNR1B 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.